{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:45:07Z","timestamp":1784940307425,"version":"3.55.0"},"reference-count":103,"publisher":"Japanese Pharmacological Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Pharmacol Sci"],"published-print":{"date-parts":[[2012]]},"DOI":"10.1254\/jphs.12r03cr","type":"journal-article","created":{"date-parts":[[2012,10,19]],"date-time":"2012-10-19T01:10:17Z","timestamp":1350609017000},"page":"77-88","source":"Crossref","is-referenced-by-count":70,"title":["Renin^|^ndash;Angiotensin System, Hypertension, and Chronic Kidney Disease: Pharmacogenetic Implications"],"prefix":"10.1254","volume":"120","author":[{"given":"Paulo Caleb Junior Lima","family":"Santos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Eduardo","family":"Krieger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre Costa","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"332","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.191261"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Brantsma AH, Bakker SJ, Hillege HL, de Zeeuw D, de Jong PE, Gansevoort RT. Cardiovascular and renal outcome in subjects with K\/DOQI stage 1-3 chronic kidney disease: the importance of urinary albumin excretion. Nephrol Dial Transplant. 2008;23:3851–3858.","DOI":"10.1093\/ndt\/gfn356"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2004.07.007"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Leoncini G, Viazzi F, Pontremoli R. Chronic kidney disease and albuminuria in arterial hypertension. Curr Hypertens Rep. 2010;12:335–341.","DOI":"10.1007\/s11906-010-0141-3"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 KDOQI. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis. 2007;49 2 Suppl 2:S12–S154.","DOI":"10.1053\/j.ajkd.2006.12.005"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–860.","DOI":"10.1056\/NEJMoa011303"},{"key":"7","unstructured":"7 National Kidney Foundation. K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39 2 Suppl 1:S1–S266."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Siragy HM, Carey RM. Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease. Am J Nephrol. 2010;31:541–550.","DOI":"10.1159\/000313363"},{"key":"9","doi-asserted-by":"crossref","unstructured":"10 Curtiss C, Cohn JN, Vrobel T, Franciosa JA. Role of the renin-angiotensin system in the systemic vasoconstriction of chronic congestive heart failure. Circulation. 1978;58:763–770.","DOI":"10.1161\/01.CIR.58.5.763"},{"key":"10","doi-asserted-by":"crossref","unstructured":"12 Nantel P, Rene de Cotret P. The evolution of angiotensin blockade in the management of cardiovascular disease. Can J Cardiol. 2010;26 Suppl E:7E–13E.","DOI":"10.1016\/S0828-282X(10)71168-5"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1038\/ng1623"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2009.07.010"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1007\/s10038-005-0270-8"},{"key":"14","doi-asserted-by":"crossref","unstructured":"18 Menard J, Bouhnik J, Clauser E, Richoux JP, Corvol P. Biochemistry and regulation of angiotensinogen. Clin Exp Hypertens A. 1983;5:1005–1019.","DOI":"10.3109\/10641968309048838"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.1086\/420793"},{"key":"16","doi-asserted-by":"crossref","unstructured":"20 Pereira TV, Nunes AC, Rudnicki M, Yamada Y, Pereira AC, Krieger JE. Meta-analysis of the association of 4 angiotensinogen polymorphisms with essential hypertension: a role beyond M235T? Hypertension. 2008;51:778–783.","DOI":"10.1161\/HYPERTENSIONAHA.107.100370"},{"key":"17","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M002615200"},{"key":"18","doi-asserted-by":"crossref","unstructured":"22 Corvol P, Michaud A, Soubrier F, Williams TA. Recent advances in knowledge of the structure and function of the angiotensin I converting enzyme. J Hypertens Suppl. 1995;13:S3–S10.","DOI":"10.1097\/00004872-199509003-00002"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00036.2005"},{"key":"20","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.74.6.584"},{"key":"21","doi-asserted-by":"crossref","unstructured":"26 Elkins JS, Douglas VC, Johnston SC. Alzheimer disease risk and genetic variation in ACE: a meta-analysis. Neurology. 2004;62:363–368.","DOI":"10.1212\/01.WNL.0000106823.72493.FF"},{"key":"22","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2004.08.208"},{"key":"23","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118369"},{"key":"24","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118270"},{"key":"25","doi-asserted-by":"crossref","unstructured":"30 Brugts JJ, Isaacs A, de Maat MP, Boersma E, van Duijn CM, Akkerhuis KM, et al. A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin-converting enzyme inhibitor therapy in patients with vascular disease and healthy individuals. J Hypertens. 2011;29:509–519.","DOI":"10.1097\/HJH.0b013e328341d117"},{"key":"26","doi-asserted-by":"crossref","unstructured":"31 Beitelshees AL, Zineh I. Renin-angiotensin-aldosterone system (RAAS) pharmacogenomics: implications in heart failure management. Heart Fail Rev. 2010;15:209–217.","DOI":"10.1007\/s10741-008-9092-z"},{"key":"27","doi-asserted-by":"crossref","unstructured":"33 Savoia C, D’Agostino M, Lauri F, Volpe M. Angiotensin type 2 receptor in hypertensive cardiovascular disease. Curr Opin Nephrol Hypertens. 2011;20:125–132.","DOI":"10.1097\/MNH.0b013e3283437fcd"},{"key":"28","doi-asserted-by":"publisher","DOI":"10.1007\/s10038-004-0129-4"},{"key":"29","doi-asserted-by":"publisher","DOI":"10.1086\/519979"},{"key":"30","doi-asserted-by":"crossref","unstructured":"37 Sharma JN. Cardiovascular activities of the bradykinin system. ScientificWorldJournal. 2008;8:384–393.","DOI":"10.1100\/tsw.2008.53"},{"key":"31","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-200303000-00029"},{"key":"32","doi-asserted-by":"crossref","unstructured":"39 Lung CC, Chan EK, Zuraw BL. Analysis of an exon 1 polymorphism of the B2 bradykinin receptor gene and its transcript in normal subjects and patients with C1 inhibitor deficiency. J Allergy Clin Immunol. 1997;99(1 Pt 1):134–146.","DOI":"10.1016\/S0091-6749(97)70310-5"},{"key":"33","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.11.4996"},{"key":"34","doi-asserted-by":"crossref","unstructured":"41 Alvarez-Madrazo S, Connell JM, Freel EM. Role of genetic variation in regulation of aldosterone biosynthesis. Endocr Dev. 2011;20:106–115.","DOI":"10.1159\/000321229"},{"key":"35","doi-asserted-by":"crossref","unstructured":"42 Nicod J, Bruhin D, Auer L, Vogt B, Frey FJ, Ferrari P. A biallelic gene polymorphism of CYP11B2 predicts increased aldosterone to renin ratio in selected hypertensive patients. J Clin Endocrinol Metab. 2003;88:2495–2500.","DOI":"10.1210\/jc.2002-021598"},{"key":"36","doi-asserted-by":"crossref","unstructured":"43 Kaparianos A, Argyropoulou E. Local renin-angiotensin II systems, angiotensin-converting enzyme and its homologue ACE2: their potential role in the pathogenesis of chronic obstructive pulmonary diseases, pulmonary hypertension and acute respiratory distress syndrome. Curr Med Chem. 2011;18:3506–3515.","DOI":"10.2174\/092986711796642562"},{"key":"37","doi-asserted-by":"crossref","unstructured":"45 De Mello WC, Frohlich ED. On the local cardiac renin angiotensin system. Basic and clinical implications. Peptides. 2011;32:1774–1779.","DOI":"10.1016\/j.peptides.2011.06.018"},{"key":"38","doi-asserted-by":"publisher","DOI":"10.1097\/01.ASN.0000071512.93927.4E"},{"key":"39","doi-asserted-by":"crossref","unstructured":"49 Singh VP, Le B, Bhat VB, Baker KM, Kumar R. High-glucose-induced regulation of intracellular ANG II synthesis and nuclear redistribution in cardiac myocytes. Am J Physiol Heart Circ Physiol. 2007;293:H939–H948.","DOI":"10.1152\/ajpheart.00391.2007"},{"key":"40","doi-asserted-by":"crossref","unstructured":"50 Balcells E, Meng QC, Johnson WH Jr, Oparil S, Dell’Italia LJ. Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am J Physiol. 1997;273(4 Pt 2):H1769–H1774.","DOI":"10.1152\/ajpheart.1997.273.4.H1769"},{"key":"41","doi-asserted-by":"crossref","unstructured":"51 Wolny A, Clozel JP, Rein J, Mory P, Vogt P, Turino M, et al. Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Circ Res. 1997;80:219–227.","DOI":"10.1161\/01.RES.80.2.219"},{"key":"42","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000121881.77212.b1"},{"key":"43","doi-asserted-by":"crossref","unstructured":"53 Ritz E, Adamczak M, Zeier M. Kidney and hypertension-causes. Update 2003. Herz. 2003;28:663–667.","DOI":"10.1007\/s00059-003-2509-5"},{"key":"44","doi-asserted-by":"crossref","unstructured":"54 Bidani AK, Griffin KA. Long-term renal consequences of hypertension for normal and diseased kidneys. Curr Opin Nephrol Hypertens. 2002;11:73–80.","DOI":"10.1097\/00041552-200201000-00011"},{"key":"45","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.9.11.2593"},{"key":"46","doi-asserted-by":"crossref","unstructured":"56 Wenzel RR. Renal protection in hypertensive patients: selection of antihypertensive therapy. Drugs. 2005;65 Suppl 2:29–39.","DOI":"10.2165\/00003495-200565002-00005"},{"key":"47","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)11445-8"},{"key":"48","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.00653.x"},{"key":"49","doi-asserted-by":"crossref","unstructured":"59 Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med. 1995;123:754–762.","DOI":"10.7326\/0003-4819-123-10-199511150-00003"},{"key":"50","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04728-0"},{"key":"51","doi-asserted-by":"crossref","unstructured":"61 Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–869.","DOI":"10.1056\/NEJMoa011161"},{"key":"52","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.10R04FM"},{"key":"53","doi-asserted-by":"crossref","unstructured":"63 Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329:1456–1462.","DOI":"10.1056\/NEJM199311113292004"},{"key":"54","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)04433-X"},{"key":"55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042167"},{"key":"56","doi-asserted-by":"crossref","unstructured":"66 Ruggenenti P, Perna A, Ganeva M, Ene-Iordache B, Remuzzi G. Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial. J Am Soc Nephrol. 2006;17:3472–3481.","DOI":"10.1681\/ASN.2006060560"},{"key":"57","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000024416.33113.0A"},{"key":"58","doi-asserted-by":"crossref","unstructured":"68 Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870–878.","DOI":"10.1056\/NEJMoa011489"},{"key":"59","doi-asserted-by":"crossref","unstructured":"69 Croom KF, Curran MP, Goa KL, Perry CM. Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy. Drugs. 2004;64:999–1028.","DOI":"10.2165\/00003495-200464090-00011"},{"key":"60","unstructured":"70 Schjoedt KJ. The renin-angiotensin-aldosterone system and its blockade in diabetic nephropathy: main focus on the role of aldosterone. Dan Med Bull. 2011;58:B4265."},{"key":"61","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-004-1542-0"},{"key":"62","doi-asserted-by":"crossref","unstructured":"72 Fyhrquist F, Saijonmaa O. Renin-angiotensin system revisited. J Intern Med. 2008;264:224–236.","DOI":"10.1111\/j.1365-2796.2008.01981.x"},{"key":"63","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.10R08FM"},{"key":"64","doi-asserted-by":"crossref","unstructured":"75 Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358:2433–2446.","DOI":"10.1056\/NEJMoa0708379"},{"key":"65","doi-asserted-by":"crossref","unstructured":"76 Persson F, Rossing P, Reinhard H, Juhl T, Stehouwer CD, Schalkwijk C, et al. Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. Diabetes Care. 2009;32:1873–1879.","DOI":"10.2337\/dc09-0168"},{"key":"66","doi-asserted-by":"crossref","unstructured":"77 Persson F, Rossing P, Schjoedt KJ, Juhl T, Tarnow L, Stehouwer CD, et al. Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. Kidney Int. 2008;73:1419–1425.","DOI":"10.1038\/ki.2008.68"},{"key":"67","doi-asserted-by":"crossref","unstructured":"78 Pimenta E, Oparil S. Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors. Ther Clin Risk Manag. 2009;5:459–464.","DOI":"10.2147\/TCRM.S5702"},{"key":"68","doi-asserted-by":"crossref","unstructured":"79 Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547–1559.","DOI":"10.1056\/NEJMoa0801317"},{"key":"69","doi-asserted-by":"crossref","unstructured":"80 Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372:1174–1183.","DOI":"10.1016\/S0140-6736(08)61242-8"},{"key":"70","unstructured":"82 Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, et al. Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). J Renin Angiotensin Aldosterone Syst. In press."},{"key":"71","doi-asserted-by":"crossref","unstructured":"83 Sullivan JC. Sex and the renin-angiotensin system: inequality between the sexes in response to RAS stimulation and inhibition. Am J Physiol Regul Integr Comp Physiol. 2008;294:R1220–R1226.","DOI":"10.1152\/ajpregu.00864.2007"},{"key":"72","doi-asserted-by":"crossref","unstructured":"84 Titan SM, Pereira AC, Cunha RS, Herkenhoff FL, Mill JG, Krieger JE. Renin-angiotensin system polymorphisms interact with blood pressure in the determination of microalbuminuria in the general population. J Hum Hypertens. 2006;20:235–237.","DOI":"10.1038\/sj.jhh.1001968"},{"key":"73","doi-asserted-by":"publisher","DOI":"10.1172\/JCI114844"},{"key":"74","doi-asserted-by":"crossref","unstructured":"87 Silva GJ, Moreira ED, Pereira AC, Mill JG, Krieger EM, Krieger JE. ACE gene dosage modulates pressure-induced cardiac hypertrophy in mice and men. Physiol Genomics. 2006;27:237–244.","DOI":"10.1152\/physiolgenomics.00023.2006"},{"key":"75","doi-asserted-by":"crossref","unstructured":"89 Jacobsen P, Rossing K, Rossing P, Tarnow L, Mallet C, Poirier O, et al. Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy. Kidney Int. 1998;53:1002–1006.","DOI":"10.1111\/j.1523-1755.1998.00847.x"},{"key":"76","doi-asserted-by":"crossref","unstructured":"90 Jacobsen P, Tarnow L, Carstensen B, Hovind P, Poirier O, Parving HH. Genetic variation in the Renin-Angiotensin system and progression of diabetic nephropathy. J Am Soc Nephrol. 2003;14:2843–2850.","DOI":"10.1097\/01.ASN.0000092139.19587.51"},{"key":"77","doi-asserted-by":"crossref","unstructured":"91 Parving HH, Jacobsen P, Tarnow L, Rossing P, Lecerf L, Poirier O, et al. Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study. BMJ. 1996;313:591–594.","DOI":"10.1136\/bmj.313.7057.591"},{"key":"78","doi-asserted-by":"crossref","unstructured":"92 So WY, Ma RC, Ozaki R, Tong PC, Ng MC, Ho CS, et al. Angiotensin-converting enzyme (ACE) inhibition in type 2, diabetic patients-- interaction with ACE insertion\/deletion polymorphism. Kidney Int. 2006;69:1438–1443.","DOI":"10.1038\/sj.ki.5000097"},{"key":"79","doi-asserted-by":"crossref","unstructured":"93 Parving HH, de Zeeuw D, Cooper ME, Remuzzi G, Liu N, Lunceford J, et al. ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy. J Am Soc Nephrol. 2008;19:771–779.","DOI":"10.1681\/ASN.2007050582"},{"key":"80","doi-asserted-by":"crossref","unstructured":"94 Nonoguchi H, Nakayama Y, Shiigai T, Inoue T, Inoue H, Kohda Y, et al. Low-responders to angiotensin II receptor blockers and genetic polymorphism in angiotensin-converting enzyme. Clin Nephrol. 2007;68:209–215.","DOI":"10.5414\/CNP68209"},{"key":"81","doi-asserted-by":"crossref","unstructured":"95 Ruggenenti P, Bettinaglio P, Pinares F, Remuzzi G. Angiotensin converting enzyme insertion\/deletion polymorphism and renoprotection in diabetic and nondiabetic nephropathies. Clin J Am Soc Nephrol. 2008;3:1511–1525.","DOI":"10.2215\/CJN.04140907"},{"key":"82","doi-asserted-by":"crossref","unstructured":"96 Ueda S, Meredith PA, Morton JJ, Connell JM, Elliott HL. ACE (I\/D) genotype as a predictor of the magnitude and duration of the response to an ACE inhibitor drug (enalaprilat) in humans. Circulation. 1998;98:2148–2153.","DOI":"10.1161\/01.CIR.98.20.2148"},{"key":"83","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-200110000-00012"},{"key":"84","doi-asserted-by":"crossref","unstructured":"98 Bhatnagar V, O’Connor DT, Schork NJ, Salem RM, Nievergelt CM, Rana BK, et al. Angiotensin-converting enzyme gene polymorphism predicts the time-course of blood pressure response to angiotensin converting enzyme inhibition in the AASK trial. J Hypertens. 2007;25:2082–2092.","DOI":"10.1097\/HJH.0b013e3282b9720e"},{"key":"85","doi-asserted-by":"crossref","unstructured":"99 Filigheddu F, Argiolas G, Bulla E, Troffa C, Bulla P, Fadda S, et al. Clinical variables, not RAAS polymorphisms, predict blood pressure response to ACE inhibitors in Sardinians. Pharmacogenomics. 2008;9:1419–1427.","DOI":"10.2217\/14622416.9.10.1419"},{"key":"86","doi-asserted-by":"publisher","DOI":"10.1291\/hypres.26.881"},{"key":"87","doi-asserted-by":"crossref","unstructured":"101 Arnett DK, Davis BR, Ford CE, Boerwinkle E, Leiendecker-Foster C, Miller MB, et al. Pharmacogenetic association of the angiotensin-converting enzyme insertion\/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study. Circulation. 2005;111:3374–3383.","DOI":"10.1161\/CIRCULATIONAHA.104.504639"},{"key":"88","doi-asserted-by":"crossref","unstructured":"102 Konoshita T, Kato N, Fuchs S, Mizuno S, Aoyama C, Motomura M, et al. Genetic variant of the renin-angiotensin system and diabetes influences blood pressure response to angiotensin receptor blockers. Diabetes Care. 2009;32:1485–1490.","DOI":"10.2337\/dc09-0348"},{"key":"89","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(92)90275-H"},{"key":"90","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000047465.97065.15"},{"key":"91","doi-asserted-by":"crossref","unstructured":"107 Schelleman H, Klungel OH, Witteman JC, Breteler MM, Yazdanpanah M, Danser AH, et al. Angiotensinogen M235T polymorphism and the risk of myocardial infarction and stroke among hypertensive patients on ACE-inhibitors or beta-blockers. Eur J Hum Genet. 2007;15:478–484.","DOI":"10.1038\/sj.ejhg.5201789"},{"key":"92","doi-asserted-by":"crossref","unstructured":"108 Su X, Lee L, Li X, Lv J, Hu Y, Zhan S, et al. Association between angiotensinogen, angiotensin II receptor genes, and blood pressure response to an angiotensin-converting enzyme inhibitor. Circulation. 2007;115:725–732.","DOI":"10.1161\/CIRCULATIONAHA.106.642058"},{"key":"93","doi-asserted-by":"crossref","unstructured":"109 Hannila-Handelberg T, Kontula KK, Paukku K, Lehtonen JY, Virtamo J, Tikkanen I, et al. Common genetic variations of the renin-angiotensin-aldosterone system and response to acute angiotensin I-converting enzyme inhibition in essential hypertension. J Hypertens. 2010;28:771–779.","DOI":"10.1097\/HJH.0b013e328335c368"},{"key":"94","doi-asserted-by":"crossref","unstructured":"111 Bonnardeaux A, Davies E, Jeunemaitre X, Fery I, Charru A, Clauser E, et al. Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. Hypertension. 1994;24:63–69.","DOI":"10.1161\/01.HYP.24.1.63"},{"key":"95","doi-asserted-by":"crossref","unstructured":"112 Wu CK, Tsai CT, Chang YC, Luo JL, Wang YC, Hwang JJ, et al. Genetic polymorphisms of the angiotensin II type 1 receptor gene and diastolic heart failure. J Hypertens. 2009;27:502–507.","DOI":"10.1097\/HJH.0b013e32831fda3a"},{"key":"96","doi-asserted-by":"crossref","unstructured":"114 Brugts JJ, de Maat MP, Danser AH, Boersma E, Simoons ML. Individualised therapy of angiotensin converting enzyme (ACE) inhibitors in stable coronary artery disease: overview of the primary results of the PERindopril GENEtic association (PERGENE) study. Neth Heart J. 2012;20:24–32.","DOI":"10.1007\/s12471-011-0173-6"},{"key":"97","doi-asserted-by":"crossref","unstructured":"117 Moore N, Dicker P, O’Brien JK, Stojanovic M, Conroy RM, Treumann A, et al. Renin gene polymorphisms and haplotypes, blood pressure, and responses to renin-angiotensin system inhibition. Hypertension. 2007;50:340–347.","DOI":"10.1161\/HYPERTENSIONAHA.106.085563"},{"key":"98","doi-asserted-by":"crossref","unstructured":"118 Yan W, Zhang Y, Shan Z, Wang Q, Huang Y, Wang C, et al. Tagging SNPs in REN, AGTR1 and AGTR2 genes and response of renin activity, angiotensin II and aldosterone concentrations to antihypertensive treatment in Kazakans. J Renin Angiotensin Aldosterone Syst. 2011;12:581–587.","DOI":"10.1177\/1470320311418266"},{"key":"99","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100214"},{"key":"100","doi-asserted-by":"crossref","unstructured":"120 Mukae S, Aoki S, Itoh S, Iwata T, Ueda H, Katagiri T. Bradykinin B(2) receptor gene polymorphism is associated with angiotensin-converting enzyme inhibitor-related cough. Hypertension. 2000;36:127–131.","DOI":"10.1161\/01.HYP.36.1.127"},{"key":"101","doi-asserted-by":"crossref","unstructured":"121 Jiang X, Sheng HH, Lin G, Li J, Lu XZ, Cheng YL, et al. Effect of renin-angiotensin-aldosterone system gene polymorphisms on blood pressure response to antihypertensive treatment. Chin Med J (Engl). 2007;120:782–786.","DOI":"10.1097\/00029330-200705010-00009"},{"key":"102","doi-asserted-by":"crossref","unstructured":"122 Farahani P, Dolovich L, Levine M. Exploring design-related bias in clinical studies on receptor genetic polymorphism of hypertension. J Clin Epidemiol. 2007;60:1–7.","DOI":"10.1016\/j.jclinepi.2006.04.002"},{"key":"103","doi-asserted-by":"crossref","unstructured":"125 Santos PC, Alvim Rde O, Ferreira NE, de Sa Cunha R, Krieger JE, Mill JG, et al. Ethnicity and arterial stiffness in Brazil. Am J Hypertens. 2011;24:278–284.","DOI":"10.1038\/ajh.2010.244"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T15:10:16Z","timestamp":1621437016000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jphs\/120\/2\/120_12R03CR\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"references-count":103,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1254\/jphs.12r03cr","relation":{},"ISSN":["1347-8613","1347-8648"],"issn-type":[{"value":"1347-8613","type":"print"},{"value":"1347-8648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012]]}}}